AbbVie Inc. (ABBV) Market Cap, Stock Prices, Chart & Financials

AbbVie Inc.

PriceChangeChange %MarketcapOpenHighLowCloseVolume52 Week RangeEPSDividend RateDividend YieldSectorIndustryEmployeesCountryLast Updated
6.9715.423.5996545HealthcareDrug Manufacturers—General50,000United States1 day ago

AbbVie Historical Market Cap (2012 – 2022)

YearMarket cap
2021$239.37 B
2020$189.17 B
2019$130.94 B
2018$136.33 B
2017$154.39 B
2016$101.76 B
2015$95.37 B
2014$104.14 B
2013$83.82 B
2012$53.97 B

AbbVie Annual Revenue & Earnings (2011 – 2022)

AbbVie Revenue & Earnings
2021$55.16 B$9.68 B
2020$45.80 B$5.85 B
2019$33.26 B$10.21 B
2018$32.75 B$6.54 B
2017$28.21 B$8.87 B
2016$25.63 B$8.93 B
2015$22.85 B$7.36 B
2014$19.96 B$2.79 B
2013$18.79 B$5.63 B
2012$18.37 B$5.71 B
2011$17.44 B$4.29 B

About The AbbVie Inc. Company

AbbVie Inc.
Sector: Healthcare
Industry: Drug Manufacturers—General
Exchange: NYQ
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.


Your email address will not be published.